medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron

Ulrike Baum[1*], Eero Poukka[1,2*†], Tuija Leino[1], Terhi Kilpi[3], Hanna Nohynek[1], Arto A. Palmu[4]

1. Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
2. University of Helsinki, Faculty of Medicine, Helsinki, Finland
3. Management, Research, Development and Innovation, Finnish Institute for Health and Welfare (THL), Helsinki, Finland
4. Population Health Unit, Department of Public Health and Welfare, Finnish Institute for Health and Welfare (THL), Tampere, Finland

* Contributed equally to this work

† Corresponding author

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract (max. 250 words)

Background.

The elderly are highly vulnerable to severe Covid-19. Waning immunity and emergence of Omicron have caused concerns about reduced effectiveness of Covid-19 vaccines. The objective was to estimate vaccine effectiveness (VE) against severe Covid-19 among the elderly.

Methods.

This nationwide, register-based cohort study included all residents aged 70 years and over in Finland. The follow-up started on December 27, 2020, and ended on February 19, 2022. The study outcomes were Covid-19-related hospitalization and intensive care unit (ICU) admission timely associated with SARS-CoV-2 infection. VE was estimated as 1 minus the hazard ratio comparing the vaccinated and unvaccinated and taking into account time since vaccination. Omicron-specific VE was evaluated as the effectiveness observed since January 01, 2022.

Results.

The cohort included 897932 individuals. Comirnaty (BioNTech/Pfizer) VE against Covid-19-related hospitalization was 93% (95% confidence interval [CI], 90%–95%) and 87% (84%–89%) 14–90 and 91–180 days after the second dose; VE increased to 96% (95%–97%) 14–60 days after the third dose. VE of other homologous and heterologous 3-dose series was similar. Protection against severe Covid-19 requiring ICU treatment was even better. Since January 01, 2022, Comirnaty VE was 91% (95% CI, 79%–96%) and 76% (56%–86%) 14–90 and 91–180 days after the second and 95% (94%–97%) 14–60 days after the third dose.

Conclusions.

VE against severe Covid-19 is high among the elderly. It waned slightly after 2 doses, but a third restored the protection. VE against severe Covid-19 remained high even after the emergence of Omicron.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

The elderly are highly vulnerable to severe Covid-19 [1] and, therefore, protecting them is essential to reduce the disease burden caused by SARS-CoV-2. Covid-19 vaccinations prevent SARS-CoV-2 infections and decrease the number of Covid-19 hospitalizations in a population [2–7].

As many other European countries, Finland has mainly used 2 mRNA vaccines, Comirnaty (BioNTech/Pfizer, available since December 27, 2020) and Spikevax (Moderna, since January 20, 2021), and 1 adenovirus vector vaccine, Vaxzevria (Oxford/AstraZeneca, from February 10 to November 30, 2021). In September 2021, Finland started its booster vaccination campaign to improve the protection especially for the elderly [8]. The initial recommendation was to adhere to homologous vaccine series, but lately with increasing evidence of good effectiveness [9,10], heterologous series have also been encouraged.

In the elderly, vaccine effectiveness (VE) against severe Covid-19 is high after the second dose, but it decreases during the following 6 months [4,11–14]. A third dose increased the VE against infection among adults in multiple observational studies [11,15–18]. However, only a few studies have investigated how well the third dose boosts the VE against severe disease among the elderly [17,19,20]. Furthermore, VE may decrease because of the recently emerged Omicron variant, which is more capable of evading both natural and vaccine-induced immunity than previous variants [15,16,21–23]. Knowledge of VE against severe Covid-19 caused by Omicron is still limited [16,21,23–25] and discussion of the need for further booster doses in the elderly has commenced.

The objective of this study was to estimate the effectiveness of Covid-19 vaccines against severe Covid-19 requiring hospitalization or intensive care unit (ICU) treatment in the elderly in Finland after 2 and 3 doses. The effects of time since vaccination, different vaccine series, age and presence of comorbidities on VE were of particular interest. In addition, this study aimed to evaluate the impact of the recently emerged Omicron variant on VE.

Methods

To estimate the effectiveness of Covid-19 vaccines in the elderly population in Finland, we conducted a nationwide, register-based cohort study starting on December 27, 2020, and ending on February 19, 2022. The study population was defined as all individuals aged 70 years and over at the beginning of the study and registered in the Population Information System as resident in Finland since January 1, 2020. The unique personal identity code assigned to all permanent residents in Finland allowed linking individual-level data from different sources.

The primary outcome was Covid-19-related hospital admission timely associated with a laboratory-confirmed (by polymerase chain reaction or antigen detection assay) SARS-CoV-2 infection. Using the Care Register for Health Care, which records data on all patients discharged from inpatient care in Finland, we defined Covid-19-related hospitalization as any inpatient encounter with a primary diagnosis of Covid-19 (International Classification of Diseases, 10th revision: U07.1, U07.2), acute respiratory tract infections (J00–J22, J46) or severe complications of lower respiratory tract infections (J80–84, J85.1, J86). A hospitalization was considered timely associated with an infection recorded in the National Infectious Diseases Register if the positive specimen was collected up to 14 days before or 7 days after the hospital admission.

The secondary outcome was Covid-19-related ICU admission. ICU admissions were identified from the Finnish Intensive Care Consortium's Quality Register for Intensive Care, which records data on all patients treated in an ICU in Finland. We considered any admission as Covid-19 related if it was marked by the

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

treating physician as due to Covid-19 and if the patient was laboratory-confirmed SARS-CoV-2 positive during the stay.

The exposure was Covid-19 vaccination recorded in the National Vaccination Register, which covers the whole population irrespective of whether they are served by public or private primary health care providers. We distinguished between the 3 vaccine brands Comirnaty, Spikevax and Vaxzevria and the number of administered doses. The time since vaccination was taken into account by categorizing the time since the last dose using the following cut points: days 21 and 84 after the first dose, days 14, 91 and 181 after the second dose, and days 14 and 61 after the third dose. Thus, a vaccinee's exposure state changed over time. Being unvaccinated was the reference state.

We considered age, sex, region of residence, residence in a long-term care facility, influenza vaccination in 2019–2020, number of nights hospitalized between 2015 and 2019 and presence of predisposing comorbidities as confounders. The first 3 confounders were taken from the Population Information System. Information on whether a subject was in long-term care at the beginning of the study or vaccinated against influenza in the last pre-pandemic season were collected from the Care Register for Social Care and the National Vaccination Register, respectively. We used the data in the Care Register for Health Care from 2015 onwards to count the number of nights hospitalized between 2015 and 2019 and to assess the presence of comorbidities that predispose to severe Covid-19 according to a recent study of predictors of Covid-19 hospitalization [26]. We completed the collection of data on predisposing comorbidities with primary health care records and prescription data as described in a previous study [3].

Each study subject was considered at risk of the primary and secondary outcomes from the beginning of the study until the first occurrence of any of the following events: outcome of interest, death, day 14 after any laboratory-confirmed SARS-CoV-2 infection, vaccination with an unidentified vaccine, a heterologous second vaccination, vaccination with the third dose prior to the start of the booster campaign (approximated by September 17, 2021), or end of study. All those events other than the outcome of interest led to censoring before the end of the study.

Using Cox regression with time in the study as the underlying time scale, we compared the hazard of the 2 outcomes in vaccinated study subjects with the corresponding hazard in the unvaccinated. The effect measure of interest was VE, quantified as 1 minus the hazard ratio adjusted for the 7 confounders categorized as outlined in Table 1. For each VE estimate, we computed either the 95% Wald confidence interval (CI) or, if there were no cases in 1 of the 2 groups, the p-value of the likelihood-ratio test. We stratified the analysis by age group and presence of comorbidities. Because of the emergence of Omicron (Supplementary Figure 1), we also estimated VE by calendar time, conducting a separate regression analysis for each quarter.

To rule out residual confounding, we quantified the association between Covid-19 vaccination and a potential negative control outcome: inpatient encounters due to injury, poisoning and certain other consequences of external causes (International Classification of Diseases, 10th revision: S00–T98) recorded in the Care Register for Health Care. Each study subject was considered at risk of this outcome from the beginning of the study until the first occurrence of any of the following events: injury, death, vaccination with an unidentified vaccine or a heterologous 2-dose series, vaccination with the third dose prior to September 17, 2021, or end of study. We compared the hazard of the control outcome in vaccinated study subjects with the corresponding hazard in the unvaccinated using Cox regression and expected to find no difference between the groups.

The significance level was set to 5%. All analyses were performed in R 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria). Results concerning the first dose, less common (less than 1200 person-years) vaccine series and the first 2 weeks after vaccination are presented in the supplementary data only.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Results

The study cohort included 897 932 individuals aged 70 years and over, and thus 99.8% of the elderly population in Finland (Supplementary Tables 1-2). At the end of the study, only 4% of those still considered at risk of Covid-19 hospitalization were unvaccinated; the majority (6% and 66%) were double- or triple-vaccinated with Comirnaty (Supplementary Table 3, Supplementary Figure 2). The median length of the dosing interval between the first and second dose and the second and third dose was 84 (interquartile range, 84–84) and 187 (interquartile range, 181–199) days, respectively. At the end of the study, the triple vaccinated who were still considered at risk of Covid-19 hospitalization had received their third dose, on average, 67 (interquartile range, 54–81) days ago. Table 1 shows the distribution of person-years by vaccination status. The younger and healthy elderly contributed proportionally less vaccinated person-time than older individuals or those with predisposing comorbidities or history of hospitalization, who had received their first dose earlier than younger and healthy individuals (Supplementary Table 3).

We observed 1522 Covid-19 hospitalizations and 234 ICU admissions, of which 637 and 131 were among the unvaccinated (Table 2, Supplementary Figure 3, Supplementary Tables 4-5). In the first 14–90 days since the second dose of Comirnaty, the VE against hospitalization was 93% (95% CI, 90%–95%). In the following 90 days, VE decreased to 87% (95% CI, 84%–89%) and subsequently rose to 96% (95% CI, 95%–97%) in the first 14–60 days since the third dose (Figure 1, Supplementary Table 6). The point estimates of VE against ICU admission were even higher (Figure 1, Supplementary Table 7). The only vaccine series with a statistically significantly lower VE than the corresponding homologous Comirnaty series was the 2-dose homologous Vaxzevria series whose effectiveness against hospitalization was 76% (95% CI, 62%–84%) in the first 91–180 days.

Increasing age and comorbidities slightly decreased the VE against hospitalization, yet the observed trend of waning remained unchanged (Supplementary Tables 8-9). In the 14–90 and 91–180 days after the second dose, the effectiveness of Comirnaty was 95% and 88% in 70-79-year-olds and 89% and 83% in 80-89-year-olds. In the 91–180 days after the second dose, the presence of either moderately or highly predisposing comorbidities reduced the VE from 92% to 83% or 84%. In the 14–60 days after the third dose of Comirnaty, the presence of comorbidities lowered the VE from 99% to 95% or 94%.

The effectiveness of Comirnaty was nearly constant over calendar time (Figure 2). In the fourth quarter of 2021 (Q4), the VE against hospitalization was 90% (95% CI, 78%–96%) in the first 14–90 days since the second vaccination and 96% (95% CI, 93%–98%) in the first 14–60 days since the third vaccination (Figure 2, Supplementary Table 10). The corresponding estimates for the first quarter of 2022 (Q1) up until February 19, which was dominated by Omicron, were 91% (95% CI, 79%–96%) and 95% (95% CI, 94%–97%), respectively (Figure 2, Supplementary Table 11). However, while in Q4 there was almost no difference in point estimates in the 14–90 and 91–180 days after the second dose, in Q1 VE seemed to drop to 76% (95% CI, 56%–86%) in the 91-180 days after the second dose (Figure 2). In both quarters, the median times since the second dose among those vaccinated 14–90 days ago (Q4: 63 days; Q1: 55 days) and 91–180 days ago (Q4: 146 days; Q1: 142 days) were similar.

The control outcome, i.e., injuries, occurred 33 044 times in the study cohort. Without differentiating between vaccines, number of doses and time since vaccination, we estimated the hazard ratio at 1.02 (95% CI, 0.98–1.06) and, thus, detected no statistically significant difference between the vaccinated and the unvaccinated. However, the hazard of injury in those vaccinated with Spikevax was higher than in the unvaccinated (Supplementary Table 12).

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Discussion

In this study of a nationwide elderly cohort, the Covid-19 vaccines used in Finland were highly effective against severe Covid-19. After the second and third dose, the VE against Covid-19-related hospitalization and ICU admission was over 90% for both Comirnaty and Spikevax. However, already during the first 6 months after the second dose, we observed signs of waning VE. Although the confidence intervals overlapped, VE against hospitalization appeared to decrease faster than VE against ICU admission. A third dose restored the level of protection to over 90%. Interestingly, the VE was nearly constant during the study period despite the sporadic emergence of new variants. However, the gradual drop in point estimates of VE against hospitalization was more evident in the first quarter of 2022, which might be an indicator of intensified waning after the second dose due to Omicron.

We found no meaningful difference in the effectiveness of the 2 mRNA vaccines. The effectiveness of Vaxzevria was, however, slightly lower, although it was still better than the average protection observed among the elderly after seasonal influenza vaccination [27,28]. Nevertheless, individuals who were first vaccinated with 2 doses of Vaxzevria and later boosted with mRNA vaccine were as well protected as those who received 3 doses of mRNA vaccine.

The present study is concordant with other studies that were conducted prior to the emergence of Omicron and found limited waning of VE against Covid-19-related hospitalization during the first 6 months after the second dose in the elderly [4,5,13,14,29]. In England, the VE against hospitalization decreased from initially excellent 98% to 91% within 5 months from the second vaccination with Comirnaty [4]. As in the present study, Vaxzevria did not offer as high protection as Comirnaty and the VE was generally lower among individuals with chronic illnesses [4]. In line with our findings, VE has also been reported to be reduced in the elderly aged 80 years and over compared to the younger elderly [14]. Due to enhanced immunosenescence and illness- or treatment-induced immunosuppression, the protection offered by Covid-19 vaccines may, thus, be weaker among the very fragile elderly, such as residents of long-term facilities.

Recent studies of adult populations have estimated the VE against severe Covid-19 caused by Omicron at 50–90% after the second dose [16,21,24,25,30] and at approximately 90% after the third dose [16,21,25,30]. Surprisingly, our results from the Omicron-dominated first quarter of 2022 match the upper limits of these estimates, although our study was restricted to elderly adults, in which VE is expected to be lower than that in younger adults [4,13,31]. High VE against severe Covid-19 caused by Omicron may partially explain the relatively low hospital burden during the Omicron wave in many European countries despite skyrocketing infection rates [32]. It is difficult to foresee how long the high level of protection will last. However, this study and another analysis [30] showed that the VE against severe Covid-19 remained at approximately 90% for at least 2–3 months after the third vaccination. The decision-making regarding the recommendation of a fourth dose for risk groups, such as the elderly, needs further evidence on the duration of natural and vaccine-induced immunity as well as VE against severe Covid-19 in various epidemiological settings.

Finland is one of the few countries that used an extended dosing interval of 12 weeks between the first and second dose due to shortage of Covid-19 vaccines in the early stage of the vaccination campaign [33]. This interval is considered more immunogenic and might enhance VE against severe disease compared to the standard dosing interval of 3–4 weeks [5,34,35]. Therefore, our results of higher VE might be explained by the longer dosing interval.

The present study has 3 major strengths. First, the nationwide cohort was highly representative as it covered essentially the whole elderly population in Finland. Second, the Finnish setting minimizes the risk of detection bias. Hospital care in Finland is equally accessible to all permanent residents due to the

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

national health insurance resulting in low or no costs. Hospitalized patients with Covid-19 symptoms have been tested at low threshold irrespective of their vaccination status and the testing capacities in hospitals were at no point exhausted. Therefore, we assume that practically all elderly Covid-19 cases with severe symptoms requiring hospital care were identified in this study. Furthermore, we were able to exclude cases with concomitant asymptomatic or mild SARS-CoV-2 infection primarily hospitalized for other reasons than Covid-19. Third, we performed a negative control outcome analysis, which demonstrated that residual confounding after covariate adjustment would be negligible. Only those vaccinated with Spikevax had a statistically significantly higher risk of injuries than the unvaccinated indicating the presence of residual confounding due to differential behavior or frailty.

Although the national registers are known to be comprehensive and have been well maintained before and during the Covid-19 pandemic, the accuracy of the data has not been validated and information bias cannot be ruled out. Another limitation is that the data do not allow estimation of variant-specific VE. As a surrogate we stratified the analysis by calendar time and used sequencing data to show which variant dominated each quarter. Due to the recent emergence of Omicron, its effect on VE in Finland can only be studied in the latest quarter. However, to provide timely estimates supporting policy makers, we ended the study prematurely before the end of the quarter reducing the statistical power of this particular analysis.

Conclusions

Since their introduction at the end of 2020, Covid-19 vaccines have been highly effective in preventing severe outcomes, such as Covid-19-related hospitalization and ICU admission, in the elderly, who carry the heaviest disease burden in a population. In our study, we observed signs of waning VE during the first 6 months after completion of a 2-dose series, but a third dose restored the high level of protection for at least 2–3 months. Our analysis of data from early 2022 suggests that the third dose still confers high protection against severe Covid-19 even after emergence of Omicron.

Notes

Acknowledgments. The authors thank Heini Salo and Toni Lehtonen for the register-based identification of individuals with medical conditions predisposing to severe Covid-19 as well as Dorothée Obach and Eveline Otte im Kampe for their valuable comments during the conceptualization of the study. Additional thanks go to all the colleagues at the Finnish Institute for Health and Welfare (THL) who curate the register data.

Authors' contributions. All authors participated in the conceptualization of the study. UB conducted the statistical analysis and EP reviewed the literature. UB and EP drafted the manuscript. All authors gave comments and revised the manuscript.

Financial support. No external funding. This study was funded by the Finnish Institute for Health and Welfare (THL).

Potential conflicts of interest. No financial conflicts related to the current work. Finnish Institute for Health and Welfare (THL) conducts Public-Private Partnership with vaccine manufacturers and has received research funding from Sanofi Inc., Pfizer Inc., and GlaxoSmithKline Biologicals SA for non-COVID-19-related studies. AAP has been an investigator in these studies but has received no personal remuneration.

References (max. 40)

1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA **2020**; 324:782.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

2. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med **2021**; :NEJMoa2113017.

3. Baum U, Poukka E, Palmu AA, Salo H, Lehtonen TO, Leino T. Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study. PLoS ONE **2021**; 16:e0258704.

4. Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med **2022**; :NEJMoa2115481.

5. Skowronski DM, Setayeshgar S, Febriani Y, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. Infectious Diseases (except HIV/AIDS), 2021. Available at: http://medrxiv.org/lookup/doi/10.1101/2021.10.26.21265397. Accessed 1 November 2021.

6. WHO. WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines. Available at: https://www.who.int/publications-detail-redirect/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines. Accessed 2 March 2022.

7. Thomas SJ, Moreira ED, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med **2021**; :NEJMoa2110345.

8. THL recommends offering a third coronavirus vaccine dose to those over 60 and for medical high-risk groups - Press release - THL. Available at: https://thl.fi/en/web/thlfi-en/-/thl-recommends-offering-a-third-coronavirus-vaccine-dose-to-those-over-60-and-for-medical-high-risk-groups. Accessed 16 December 2021.

9. Poukka E, Baum U, Palmu AA, et al. Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021. Vaccine **2021**; :S0264410X21016406.

10. Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. The Lancet Regional Health - Europe **2021**; :100249.

11. Berec L, Šmíd M, Přibylová L, et al. Real-life protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in the Czech Republic: a whole country retrospective view. Epidemiology, 2021. Available at: http://medrxiv.org/lookup/doi/10.1101/2021.12.10.21267590. Accessed 15 December 2021.

12. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med **2021**; :NEJMoa2114228.

13. Lin D-Y, Gu Y, Wheeler B, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. N Engl J Med **2022**; :NEJMoa2117128.

14. Machado A, Kislaya I, Rodrigues AP, et al. COVID-19 vaccine effectiveness against laboratory confirmed symptomatic SARS-CoV-2 infection, COVID-19 related hospitalizations and deaths, among individuals aged 65 years or more in Portugal: a cohort study based on data-linkage of national registries February-September 2021. Epidemiology, 2021. Available at: http://medrxiv.org/lookup/doi/10.1101/2021.12.10.21267619. Accessed 15 December 2021.

15. Hansen CH, Schelde AB, Moustsen-Helm IR, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

vaccination series: A Danish cohort study. Infectious Diseases (except HIV/AIDS), 2021. Available at: http://medrxiv.org/lookup/doi/10.1101/2021.12.20.21267966. Accessed 4 January 2022.

16. Buchan SA, Chung H, Brown KA, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. Infectious Diseases (except HIV/AIDS), 2022. Available at: http://medrxiv.org/lookup/doi/10.1101/2021.12.30.21268565. Accessed 1 February 2022.

17. Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2 Booster across Age Groups. N Engl J Med **2021**; :NEJMoa2115926.

18. Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. Epidemiology, 2021. Available at: http://medrxiv.org/lookup/doi/10.1101/2021.12.14.21267615. Accessed 2 March 2022.

19. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. The Lancet **2021**; :S0140673621022492.

20. Drawz PE, DeSilva M, Bodurtha P, et al. Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for SARS-CoV-2 infection and SARS-CoV-2 Related Hospitalizations: A Statewide Report from the Minnesota Electronic Health Record Consortium. Clinical Infectious Diseases **2022**; :ciac110.

21. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. MMWR Morb Mortal Wkly Rep **2022**; 71:139–145.

22. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med **2022**; Available at: https://www.nature.com/articles/s41591-022-01753-y. Accessed 2 March 2022.

23. Kahn F, Bonander C, Moghaddassi M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022. Eurosurveillance **2022**; 27. Available at: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.9.2200121. Accessed 8 March 2022.

24. Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med **2021**; :NEJMc2119270.

25. Public Health England. COVID-19 vaccine surveillance report - week 8. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1057599/Vaccine_surveillance_report_-_week-8.pdf. Accessed 2 March 2022.

26. Salo H, Lehtonen T, Auranen K, Baum U, Leino T. Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: a population-based register study with implications to vaccinations. Epidemiology, 2021. Available at: http://medrxiv.org/lookup/doi/10.1101/2021.07.04.21259954. Accessed 19 January 2022.

27. Baum U, Kulathinal S, Auranen K. Spotlight influenza: Estimation of influenza vaccine effectiveness in elderly people with assessment of residual confounding by negative control outcomes, Finland, 2012/13 to 2019/20. Eurosurveillance **2021**; 26. Available at:

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.36.2100054. Accessed 12 January 2022.

28. Rose A, Kissling E, Emborg H-D, et al. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Eurosurveillance **2020**; 25. Available at: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000153. Accessed 2 March 2022.

29. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. The Lancet **2021**; :S0140673621021838.

30. Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar. Epidemiology, 2022. Available at: http://medrxiv.org/lookup/doi/10.1101/2022.02.07.22270568. Accessed 9 February 2022.

31. Lytras T, Kontopidou F, Lambrou A, Tsiodras S. Comparative effectiveness of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign. Epidemiology, 2022. Available at: http://medrxiv.org/lookup/doi/10.1101/2022.01.28.22270009. Accessed 1 February 2022.

32. Mathieu E. How do key COVID-19 metrics compare to previous waves? Available at: https://ourworldindata.org/covid-metrics-previous-waves. Accessed 2 March 2022.

33. Expert group on vaccines recommends longer gap between coronavirus vaccinations and giving AstraZeneca vaccine to those under 70 - Press release - THL. Available at: https://thl.fi/en/web/thlfi-en/-/expert-group-on-vaccines-recommends-longer-gap-between-coronavirus-vaccinations-and-giving-astrazeneca-vaccine-to-those-under-70. Accessed 1 April 2021.

34. Payne RP, Longet S, Austin JA, et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell **2021**; 184:5699-5714.e11.

35. Amirthalingam G, Bernal JL, Andrews NJ, et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nat Commun **2021**; 12:7217.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Tables

Table 1. Distribution of person-years in the study of vaccine effectiveness against Covid-19 hospitalization. This tabulation uses a binary vaccination status without distinguishing between vaccine brands, number of doses and time since vaccination.

	Not vaccinated, person-years (%)	Vaccinated, person-years (%)
Age in years		
70-79	171 816 (26)	480 532 (74)
80-89	57 024 (20)	223 267 (80)
90-115	12 790 (23)	43 687 (77)
Sex		
Male	104 371 (25)	316 048 (75)
Female	137 258 (24)	431 438 (76)
Region of residence		
Helsinki-Uusimaa	55 738 (23)	182 496 (77)
Åland	1130 (21)	4343 (79)
Northern and Eastern Finland	60 654 (25)	185 294 (75)
Southern Finland	58 517 (25)	177 691 (75)
Western Finland	65 590 (25)	197 663 (75)
In long-term care		
No	233 001 (25)	707 795 (75)
Yes	8629 (18)	39 691 (82)
Influenza vaccination in 2019–2020		
No	130 699 (30)	302 083 (70)
Yes	110 930 (20)	445 403 (80)
Nights hospitalized between 2015 and 2019		
0	131 127 (25)	386 023 (75)
1-5	49 542 (23)	163 688 (77)
6-20	35 150 (23)	114 631 (77)
21+	25 811 (24)	83 144 (76)
Presence of comorbidities[a]		
No predisposing comorbidities	106 823 (25)	312 782 (75)
Moderately predisposing comorbidities only	52 882 (24)	170 635 (76)
At least 1 highly predisposing comorbidity	81 925 (24)	264 069 (76)
Presence of particular comorbidities[a]		
Diabetes mellitus type 2	51 465 (24)	165 036 (76)
Heart failure or ischemic heart disease	42 614 (23)	140 974 (77)
Malignant neoplasms	27 975 (23)	93 192 (77)
Asthma	18 906 (23)	64 024 (77)
Chronic pulmonary disease	7412 (26)	21 426 (74)
Chronic renal disease	5410 (24)	17 236 (76)
Hematologic malignancy	3866 (24)	12 460 (76)
Diseases of myoneural junction and muscle	1569 (26)	4535 (74)
Organ or stem cell transplant	556 (24)	1798 (76)
Cerebral palsy or other paralytic syndromes	501 (24)	1606 (76)
Severe disorders of the immune system	372 (24)	1163 (76)

[a] See study of predictors of Covid-19 hospitalization [26].

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2. Cases, person-years and cumulative risk (per 100 000) estimated based on the Kaplan-Meier estimator in the elderly population in Finland by vaccine, dose and days since last vaccination.

	Covid-19-related hospital admission			Covid-19-related ICU admission		
	Cases	Person-years	Risk	Cases	Person-years	Risk
Not vaccinated	637	241 629	888	131	241 644	157
Comirnaty + Comirnaty 14-90	30	143 799	80	<5	143 800	8
Comirnaty + Comirnaty 91-180	193	156 943	148	24	156 948	13
Comirnaty + Comirnaty 181+	148	28 696	265	14	28 701	23
Comirnaty + Comirnaty + Comirnaty 14-60	79	64 209	28	9	64 212	2
Comirnaty + Comirnaty + Comirnaty 61+	66	22 182	60	8	22 183	52
Comirnaty + Comirnaty + Spikevax 14-60	13	6544	73	<5	6544	9
Spikevax + Spikevax 14-90	<5	16 454	56	0	16 455	0
Spikevax + Spikevax 91-180	30	17 576	84	<5	17 577	2
Spikevax + Spikevax 181+	14	2962	151	0	2963	0
Spikevax + Spikevax + Comirnaty 14-60	<5	1924	90	0	1924	0
Spikevax + Spikevax + Spikevax 14-60	5	5677	14	0	5677	0
Spikevax + Spikevax + Spikevax 61+	<5	1379	21	0	1379	0
Vaxzevria + Vaxzevria 14-90	<5	8263	16	<5	8263	10
Vaxzevria + Vaxzevria 91-180	23	9082	205	5	9083	13
Vaxzevria + Vaxzevria + Comirnaty 14-60	<5	2535	24	0	2536	0

medRxiv preprint doi: https://doi.org/10.1101/2022.03.11.22272140; this version posted March 13, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure legends

Figure 1. Vaccine effectiveness against primary outcomes in the elderly population in Finland by vaccine, dose and days since last vaccination. All estimates are statistically significantly different from 0%.

Figure 2. Comirnaty vaccine effectiveness against primary outcomes in the elderly population in Finland by quarter, dose and days since last vaccination. The most recent quarter (2022 Q1) only covers the period from January 01 to February 19. A filled symbol indicates that the estimate is statistically significantly different from 0%, while an empty symbol indicates that the estimate is not statistically significantly different from 0%.


Covid-19-related hospital admission
Covid-19-related ICU admission
Comirnaty + Comirnaty 14-90
Comirnaty + Comirnaty 91-180
Comirnaty + Comirnaty 181+
Comirnaty + Comirnaty + Comirnaty 14-60
Comirnaty + Comirnaty + Comirnaty 61+
Comirnaty + Comirnaty + Spikevax 14-60
Spikevax + Spikevax 14-90
Spikevax + Spikevax 91-180
Spikevax + Spikevax 181+
Spikevax + Spikevax + Comirnaty 14-60
Spikevax + Spikevax + Spikevax 14-60
Spikevax + Spikevax + Spikevax 61+
Vaxzevria + Vaxzevria 14-90
Vaxzevria + Vaxzevria 91-180
Vaxzevria + Vaxzevria + Comirnaty 14-60
0
25
50
75
100
Vaccine effectiveness, %

Comirnaty + Comirnaty 14-90
Comirnaty + Comirnaty 91-180
Comirnaty + Comirnaty 181+
Comirnaty + Comirnaty + Comirnaty 14-60
Comirnaty + Comirnaty + Comirnaty 61+
Covid-19-related hospital admission
Covid-19-related ICU admission
Vaccine effectiveness, %
100
75
50
25
0
2021 Q1
2021 Q2
2021 Q3
2021 Q4
2022 Q1